Medical management of influenza infection

Annual Review of Medicine

Volumn 59, Issue , 2008, Pages 397-413

  Moscona, Anne ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antiviral; Drug resistance; Neuraminidase inhibitor; Prophylaxis

Indexed keywords

ADAMANTANE; AMANTADINE; ANTIVIRUS AGENT; CYANOVIRIN N; FLUDASE; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; RIMANTADINE; SIALIDASE FUSION PROTEIN; SIALIDASE INHIBITOR; SMALL INTERFERING RNA; T 705; TARIBAVIRIN; UNCLASSIFIED DRUG; ZANAMIVIR;

ABDOMINAL PAIN; AVIAN INFLUENZA; BEHAVIOR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; DRUG EFFICACY; EXPOSURE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; UNSPECIFIED SIDE EFFECT; VIRION; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; VOMITING;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 39649114107     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.59.061506.213121     Document Type: Review

References (90)

1. Moscona A. 2005. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353:1363-73
2. Govorkova E, Fang H, Tan M, Webster R. 2004. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob. Agents Chemother. 48:4855-63
3. Bright RA, Medina MJ, Xu X, et al. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:1175-81
4. Bright RA, Shay DK, Shu B, et al. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-94
5. Centers for Disease Control. 2006. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5502a7.htm. Accessed Apr. 30, 2007
6. Weinstock DM, Zuccotti G. 2006. Adamantane resistance in influenza A. JAMA 295:934-36
7. Zoidis G, Fytas C, Papanastasiou I, et al. 2006. Heterocyclic rimantadine analogues with antiviral activity. Bioorg. Med. Chem. 14:3341-48
8. De Clercq E. 2006. Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 5:1015-25
9. Moscona A. 2005. Oseltamivir resistance - disabling our influenza defenses. N. Engl. J. Med. 353:2633-36
10. Colman PM, Varghese JN, Laver WG. 1983. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41-44
11. Varghese J, McKimm-Breschkin J, Caldwell JB, et al. 1992. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins Struct. Funct. Genet. 14:327-32
12. Varghese JN, Epa VC, Colman PM. 1995. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci. 4:1081-87
13. von Itzstein M, Wu W-Y, Kok G, et al. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-23
14. Kim C, Lew W, Williams M, et al. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119:681-90
15. Beigel JH, Farrar J, Han AM, et al. 2005. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353:1374-85
16. Schunemann HJ, Hill SR, Kakad M, et al. 2007. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect. Dis. 7:21-31
17. Kaiser L, Wat C, Mills T, et al. 2003. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med. 163:1667-72
18. Aoki FY, Macleod MD, Paggiaro P, et al. 2003. Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother. 51:123-29
19. Kawai N, Ikematsu H, Iwaki N, et al. 2005. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin. Infect. Dis. 40:1309-16
20. Hedrick JA, Barzilai A, Behre U, et al. 2000. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr. Infect. Dis. J. 19:410-17
21. Whitley RJ, Hayden FG, Reisinger KS, et al. 2001. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20:127-33
22. Kawai N, Ikematsu H, Iwaki N, et al. 2006. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin. Infect. Dis. 43:439-44
23. Sugaya N, Mitamura K, Yamazaki M, et al. 2007. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin. Infect. Dis. 44:197-202
24. McKimm-Breschkin J, Trivedi T, Hampson A, et al. 2003. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47:2264-72
25. Taylor N, Cleasby A, Singh O, et al. 1998. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. J. Med. Chem. 41:798-807
26. Moscona A, McKimm-Breschkin J. 2007. News about influenza B drug resistance that cannot be ignored. JAMA 297:1492-93
27. Peters PH Jr., Gravenstein S, Norwood P, et al. 2001. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J. Am. Geriatr. Soc. 49:1025-31
28. Hayden FG, Belshe R, Villanueva C, et al. 2004. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J. Infect. Dis. 189:440-49
29. Smee DF, Huffman JH, Morrison AC, et al. 2001. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob. Agents Chemother. 45:743-48
30. Barroso L, Treanor J, Gubareva L, Hayden FG. 2005. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antiviral Ther. 10:901-10
31. Bantia S, Arnold CS, Parker CD, et al. 2006. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 69:39-45
32. Sidwell RW, Bailey KW, Wong M-H, et al. 2006. Effect of single i. m. or i. v. injection of peramivir on an influenza A (H5N1) virus infection in mice. Antiviral Res. 70:A50 (Abstr.)
33. Calfee DP, Peng AW, Cass LM, et al. 1999. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob. Agents Chemother. 43:1616-20
34. Fritz RS, Hayden FG, Calfee DP, et al. 1999. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J. Infect. Dis. 180:586-93
35. Macdonald SJF, Watson KG, Cameron R, et al. 2004. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob. Agents Chemother. 48:4542-49
36. Freund B, Gravenstein S, Elliott M, Miller I. 1999. Zanamivir: a review of clinical safety. Drug Safety 21:267-81
37. Murphy K, Eivindson A, Pauksens K, et al. 2000. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructuve pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin. Drug Invest. 20:337-49
38. Nicholson KG, Aoki FY, Osterhaus AD, et al. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355:1845-50
39. Pharmalot. 2007. Japan to review "Tamiflu suicide." Available at http://pharmalot.com/2007/03/japan_to_review_tamiflu_suicid.php. Accessed May 8, 2007
40. MacKenzie D. 2007. Japan bans Tamiflu for teenagers (Mar. 23, 2007). NewScientist.com news service. Available at http://www.newscientist.com/ article/dn11451-japan-bans-tamiflu-for-teenagers-.html. Accessed May 8, 2007
41. Hankyoreh. 2007. S. Korea to virtually ban use of Tamiflu by teenagers (April 5, 2007). Yonhap News. Available at http://english.hani.co.kr/ arti/english_edition/e_national/201087.html. Accessed May 8, 2007
42. Ungchusak K, Auewarakul P, Dowell SF, et al. 2005. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 352:333-40
43. WHO. 2007. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. Available at http://www.who.int/csr/disease/ avian_influenza/country/cases_table_2007_04_11/en/index.html. Accessed May 2, 2007
44. Li KS, Guan Y, Wang J, et al. 2004. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430:209-13
45. Stohr K. 2005. Avian influenza and pandemics - research needs and opportunities. N. Engl. J. Med. 352:405-7
46. Hayden FG. 2001. Perspectives on antiviral use during pandemic influenza. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:1877-84
47. CSIRO. 2004. CSIRO based drug effective against bird flu. http://www.csiro.au/index.asp?type=mediaRelease&docid= PrBirdFlu5&style=mediarelease. Accessed Feb. 20, 2004
48. Trampuz A, Prabhu RM, Smith TF, Baddour LM. 2004. Avian influenza: a new pandemic threat? Mayo Clin. Proc. 79:523-30
49. Macken C, Lu H, Goodman J, Boykin L. 2001. The value of a database in surveillance and vaccine selection. In Options for the Control of Influenza IV, ed. ADME Osterhaus, N Cox, AW Hampson, pp. 103-5. Amsterdam: Elsevier Sci.
50. Tumpey TM, Garcia-Sastre A, Mikulasova A, et al. 2002. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc. Natl. Acad. Sci. USA 99:13849-54
51. Leneva IA, Goloubeva O, Fenton RJ, et al. 2001. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob. Agents Chemother. 45:1216-24
52. Leneva IA, Roberts N, Govorkova EA, et al. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 48:101-15
53. Govorkova EA, Ilyushina NA, Boltz DA, et al. 2007. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 51:1414-24
54. Yen HL, Monto AS, Webster RG, Govorkova EA. 2005. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J. Infect. Dis. 192:665-72
55. Gubareva LV, McCullers JA, Bethell RC, Webster RG. 1998. Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J. Infect. Dis. 178:1592-96
56. Cass LM, Brown J, Pickford M, et al. 1999. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin. Pharmacokinet. 36(Suppl. 1):21-31
57. Peng AW, Milleri S, Stein DS. 2000. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob. Agents Chemother. 44:1974-76
58. de Jong MD, Simmons CP, Thanh TT, et al. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12:1203-7
59. Le QM, Kiso M, Someya K, et al. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108
60. Neuraminidase Inhibitor Susceptibility Network. 2007. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Wkly. Epidemiol. Rec. 27:149-50
61. Hatakeyama S, Sugaya N, Ito M, et al. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-42
62. McKimm-Breschkin J. 2000. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res. 47:1-17
63. Varghese JN, Smith PW, Sollis SL, et al. 1998. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6:735-46
64. Deleted in proof
65. Zurcher T, Yates PJ, Daly J, et al. 2006. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J. Antimicrob. Chemother. 58:723-32
66. Smith B, McKimm-Breschkin J, McDonald M, et al. 2002. Structural studies of the resistance of influenza virus neuramindase to inhibitors. J. Med. Chem. 45:2207-12
67. WHO. 2007. Avian influenza - situation in Egypt - update. Available at http://www.who.int/csr/don/2007_01_18/en/index.html. Accessed May 3, 2007
68. Herlocher ML, Truscon R, Elias S, et al. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190:1627-30
69. Ferguson NM, Mallett S, Jackson H, et al. 2003. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J. Antimicrob. Chemother. 51:977-90
70. Lipsitch M, Cohen T, Murray M, Levin BR. 2007. Antiviral resistance and the control of pandemic influenza. PLoS Med. 4:e15
71. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. 2006. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 70:121-31
72. Malakhov MP, Aschenbrenner LM, Smee DF, et al. 2006. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother. 50:1470-79
73. O'Keefe BR, Smee DF, Turpin JA, et al. 2003. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 47:2518-25
74. Ge Q, Filip L, Bai A, et al. 2004. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA 101:8676-81
75. Tompkins SM, Lo CY, Tumpey TM, Epstein SL. 2004. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA 101:8682-86
76. Furuta Y, Takahashi K, Fukuda Y, et al. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46:977-81
77. Sidwell RW, Bailey KW, Wong MH, et al. 2005. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res. 68:10-17
78. Hayden FG, Sable CA, Connor JD, Lane J. 1996. Intravenous ribavirin by constant infusion for serious influenza and Parainfluenzavirus infection. Antiviral Ther. 1:51-56
79. Marjuki H, Alam MI, Ehrhardt C, et al. 2006. Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activation of ERK signaling. J. Biol. Chem. 281:16707-15
80. Pleschka S, Wolff T, Ehrhardt C, et al. 2001. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat. Cell Biol. 3:301-5
81. Ichinohe T, Watanabe I, Ito S, et al. 2005. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79:2910-19
82. Twu KY, Noah DL, Rao P, et al. 2006. The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target. J. Virol. 80:3957-65
83. Akaike T, Noguchi Y, Ijiri S, et al. 1996. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. USA 93:2448-53
84. Akaike T, Okamoto S, Sawa T, et al. 2003. 8-nitroguanosine formation in viral pneumonia and its implication for pathogenesis. Proc. Natl. Acad. Sci. USA 100:685-90
85. Kacergius T, Ambrozaitis A, Deng Y, Gravenstein S. 2006. Neuraminidase inhibitors reduce nitric oxide production in influenza virus-infected and gamma interferon-activated RAW 264.7 macrophages. Pharmacol. Rep. 58:924-30
86. Almog Y, Shefer A, Novack V, et al. 2004. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880-85
87. Frost FJ, Petersen H, Tollestrup K, Skipper B. 2007. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 131:1006-12
88. Kobasa D, Takada A, Shinya K, et al. 2004. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 431:703-7
89. Osterholm MT. 2005. Preparing for the next pandemic. N. Engl. J. Med. 352:1839-42
90. Kobasa D, Jones SM, Shinya K, et al. 2007. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445:319-23